Jump to navigation Jump to search
Clinical data
  • AU: D
ATC code
Legal status
Legal status
  • Withdrawn from market
Pharmacokinetic data
Elimination half-life2–3 hours
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Molar mass459.55 g/mol
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

WikiDoc Resources for Cerivastatin


Most recent articles on Cerivastatin

Most cited articles on Cerivastatin

Review articles on Cerivastatin

Articles on Cerivastatin in N Eng J Med, Lancet, BMJ


Powerpoint slides on Cerivastatin

Images of Cerivastatin

Photos of Cerivastatin

Podcasts & MP3s on Cerivastatin

Videos on Cerivastatin

Evidence Based Medicine

Cochrane Collaboration on Cerivastatin

Bandolier on Cerivastatin

TRIP on Cerivastatin

Clinical Trials

Ongoing Trials on Cerivastatin at Clinical Trials.gov

Trial results on Cerivastatin

Clinical Trials on Cerivastatin at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Cerivastatin

NICE Guidance on Cerivastatin


FDA on Cerivastatin

CDC on Cerivastatin


Books on Cerivastatin


Cerivastatin in the news

Be alerted to news on Cerivastatin

News trends on Cerivastatin


Blogs on Cerivastatin


Definitions of Cerivastatin

Patient Resources / Community

Patient resources on Cerivastatin

Discussion groups on Cerivastatin

Patient Handouts on Cerivastatin

Directions to Hospitals Treating Cerivastatin

Risk calculators and risk factors for Cerivastatin

Healthcare Provider Resources

Symptoms of Cerivastatin

Causes & Risk Factors for Cerivastatin

Diagnostic studies for Cerivastatin

Treatment of Cerivastatin

Continuing Medical Education (CME)

CME Programs on Cerivastatin


Cerivastatin en Espanol

Cerivastatin en Francais


Cerivastatin in the Marketplace

Patents on Cerivastatin

Experimental / Informatics

List of terms related to Cerivastatin

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Cerivastatin (brand names: Baycol, Lipobay) is a synthetic member of the class of statins used to lower cholesterol and prevent cardiovascular disease. It was marketed by the pharmaceutical company Bayer A.G. in the late 1990s, competing with Pfizer's highly successful atorvastatin (Lipitor). Cerivastatin was voluntarily withdrawn from the market worldwide in 2001, due to reports of fatal rhabdomyolysis.

During postmarketing surveillance, 52 deaths were reported in patients using cerivastatin, mainly from rhabdomyolysis and its resultant renal failure.[1] Risks were higher in patients using fibrates, mainly gemfibrozil (Lopid), and in patients using the highest (0.8 mg/day) dose of cerivastatin. Bayer A.G. added a contraindication for the concomitant use of cerivastatin and gemfibrozil to the package 18 months after the drug interaction was found.[2] The frequency of deadly cases of rhabdomyolysis with cerivastatin was 16 to 80 times higher than with other statins.[3] Another 385 nonfatal cases of rhabdomyolysis were reported. This put the risk of this (rare) complication at 5-10 times that of the other statins. Cerivastatin also induced myopathy in a dose-dependent manner when administered as monotherapy, but that was revealed only after Bayer was sued and unpublished company documents were opened.[4]


  1. Furberg CD, Pitt B. Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiovasc Med 2001;2:205-207. PMID 11806796.
  2. Psaty BM, Furberg CD, Ray WA, Weiss NS (2004). "Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis". JAMA. 292 (21): 2622–31. doi:10.1001/jama.292.21.2622. PMID 15572720.
  3. Zeitlinger M, Müller M (2003). "[Clinico-pharmacologic explanation models of cerivastatin associated rhabdomyolysis]". Wien Med Wochenschr (in German). 153 (11–12): 250–4. doi:10.1046/j.1563-258X.2003.03029.x. PMID 12879633.
  4. Saito M, Hirata-Koizumi M, Miyake S, Hasegawa R (2005). "[Withdrawal of cerivastatin revealed a flaw of post-marketing surveillance system in the United States]". Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku (in Japanese) (123): 41–5. PMID 16541751.